Search the Newsreel

XENE Q2 2026 Earnings: Narrower-Than-Expected Loss Signals Cost Discipline - Earnings Growth Forecast

MarketAxess (MKTX) Earnings Date and Reports 2026

Xenon Pharmaceuticals (NASDAQ:XENE) Announces Quarterly Earnings Results

Xenon Pharmaceuticals Inc (XENE) (Q2 2026) Earnings Call Highlights: Advancing Azetukalner ...

Xenon Pharmaceuticals Inc. (XENE) Q2 2026 earnings call highlighted significant progress in advancing azetukalner, with a successful pre-NDA meeting for focal seizures and a strong cash position of $1.2 billion, funding operations into 2029. The company also detailed its broad pipeline, including five additional …

NewtekOne Inc (NEWT) (Q2 2026) Earnings Call Highlights: Strategic Shift to Bank-Centric Model ...

NewtekOne Inc (NEWT) reported strong Q2 2026 earnings with significant asset growth and successful deposit gathering, driven by a strategic shift towards a bank-centric model focusing on net interest income. However, the company withdrew its Q4 2026 EPS guidance due to this shift, which …

EXELIXIS INC : LEERINK PARTNERS CUTS TO MARKET PERFORM FROM OUTPERFORM

Leerink Partners has downgraded its rating for Exelixis Inc (EXEL.O) from "Outperform" to "Market Perform." This change indicates a revised outlook on the pharmaceutical company's stock performance. The update was reported by Reuters.

Crexendo, Inc. (CXDO) CEO RSUs vest as 68 shares withheld for taxes

Crexendo, Inc. CEO Jeffrey G. Korn reported the vesting of 278 Restricted Stock Units (RSUs) into common stock on August 4, 2026. The company withheld 68 shares, valued at $7.47 each, to cover payroll tax obligations, a transaction explicitly stated not to be a …

Xeris Biopharma Holdings, Inc. reports results for the quarter ended June 30 - Earnings Summary

Xeris Biopharma Holdings, Inc. has released its earnings summary for the quarter that concluded on June 30. The report is provided by Refinitiv and is available to TradingView users with unlimited access to news articles.

Xeris Pharmaceuticals’ Earnings Call Highlights Growth Momentum

Key Points Interested in Xeris Biopharma Holdings, Inc.? Here are five stocks we like better. Xeris Biopharma's second-quarter revenue rose 29% year over year to $92.1 million, driven by a 34% increase in net product revenue. Adjusted EBITDA grew more than 50% to $19.3 …

Crexendo (CXDO) CFO notes 278 RSUs vested, 118 shares withheld for taxes

Crexendo, Inc.'s CFO, Vincent Ron, reported the vesting of 278 Restricted Stock Units (RSUs) on August 4, 2026. The company withheld 118 common shares at $7.47 per share to cover payroll taxes, clarifying that this was not a market sale. Ron retains 8,334 RSUs, …

Xenon Reports Q2 2026 Financial Results and Provides Business Update

Xenon Pharmaceuticals Inc. announced its Q2 2026 financial results, highlighted by the continued progress of its lead drug azetukalner, with an NDA submission for FOS on track for Q3 2026 and Phase 3 data for MDD expected in H1 2027. The company reported $1.2 …

Xenetic Biosciences, Inc. 2026: Revenue $660.6K, EPS ($0.41) — 10-Q Summary

Xenetic Biosciences, Inc. (XBIO) reported its 2026 quarterly results with revenue of $660.6K, a 12% increase year-over-year, and a diluted loss per share of ($0.41). The company's net loss was ($929.7K), an increase of 35% from the prior year quarter. Revenue growth was primarily …

Exelixis (EXEL) Is Down 6.7% After Cutting 2026 Revenue Outlook Amid Oncology Investment Pivot

Exelixis (EXEL) saw its stock drop 6.7% after cutting its 2026 revenue outlook to $2.50 billion–$2.55 billion. This revision came despite solid Q2 earnings and is attributed to slower growth in the neuroendocrine tumor indication and continued heavy investment in its zanzalintinib pipeline and …

NewtekOne Q2 2026 slides: deposit growth powers earnings, valuation gap widens

NewtekOne (NASDAQ: NEWT) reported strong Q2 2026 results, with diluted EPS of $0.47, driven by significant deposit growth and a lower-cost infrastructure. The company is transitioning from a specialty finance lender to a digital banking platform, evidenced by substantial tangible book value growth and …

NewtekOne, Inc. Reports 2Q26 Basic and Diluted EPS of $0.48 and $0.47

NewtekOne, Inc. reported its financial and operating results for the second quarter of 2026, with basic and diluted EPS of $0.48 and $0.47, respectively. The company saw significant growth in non-affiliate business deposits and strong loan originations across various categories. CEO Barry Sloane highlighted …

PRIMECAP Management (MKTX) discloses 3.5M-share MarketAxess position in 13G/A

PRIMECAP Management Co./CA/ has filed an amended Schedule 13G disclosing its position in MarketAxess Holdings Inc. (MKTX). The firm beneficially owns 3,504,905 shares, which represents 9.86% of the outstanding common stock. PRIMECAP Management has sole voting power over 3,481,055 shares and sole dispositive power …

Earnings Flash (XENE) Xenon Pharmaceuticals Inc. Reports Q2 Revenue $0

Pixelworks, Inc. (PXLW.US) will release its earnings report after market close on August 11.

Pixelworks, Inc. (PXLW.US) is scheduled to release its earnings report after the market closes on August 11. Investors and analysts will be watching the announcement for insights into the company's financial performance.

Xenon Pharmaceuticals earnings on deck as FDA approval push nears

Xenon Pharmaceuticals is set to release its second-quarter earnings, with investors keenly watching its cash position and regulatory timeline as it approaches an FDA submission for its drug, azetukalner. Analysts anticipate a loss of $1.14 per share on $1.5 million in revenue. The company …

Xencor Reports Fourth Quarter and Full Year 2025 Financial Results

Xencor, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2025, highlighting advancements in its oncology and autoimmune disease pipelines. Key updates include the progress of XmAb819 in clinical trials for various cancers, the advancement of XmAb942 and …

Does Xencor’s Mixed 2026 Loss Trend Reshape the Investment Narrative Around XNCR’s R&D Priorities?

Xencor, Inc. reported mixed Q2 and half-year 2026 results, with a narrowing net loss for the quarter but a widened net loss for the first six months. This financial divergence highlights the impact of R&D spending on the company's profile and prompts a re-evaluation …

Deluxe (DLX) Earnings Beat Puts Its Valuation Back In Focus

EXELIXIS, INC. Q2 2026: Revenue $628.69M, EPS $0.82— 10-Q Summary

EXELIXIS, INC. reported strong second-quarter 2026 results with revenue of $628.69M and diluted EPS of $0.82, showing significant year-over-year growth due to increased product demand and price gains. Key drivers included CABOMETYX sales, progress in pipeline development with zanzalintinib, and expanded clinical trials. The …

Exelixis Inc (EXEL) Beats EPS Estimate with $0.82 and Reports Revenue of $628.7 Million -- Is the Stock Overvalued?

Exelixis Inc (EXEL) reported strong financial results for Q2 2026, surpassing analyst expectations with total revenues of $628.7 million and a GAAP diluted EPS of $0.82. The biopharmaceutical company, known for its cancer treatments like cabozantinib, updated its fiscal year 2026 guidance, projecting total …

The M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—FBRX, LXFR, SMTI, and MKTX

NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class …

Xencor (NASDAQ:XNCR) Hits New 52-Week High Following Better-Than-Expected Earnings

Xencor (NASDAQ:XNCR) shares reached a new 52-week high after reporting better-than-expected quarterly earnings and revenue. The biopharmaceutical company posted an EPS of $(0.29), significantly beating the consensus estimate of $(0.80), and revenue of $51.22 million, surpassing expectations. Despite remaining unprofitable with a negative net …

FMR LLC and Abigail Johnson report 9.9% Xenon Pharmaceuticals (XENE) holding

FMR LLC and Abigail Johnson have reported a 9.9% beneficial ownership stake in Xenon Pharmaceuticals Inc. (XENE) as of June 30, 2026. FMR LLC holds 9,599,498 common shares with sole dispositive power and sole voting power over 9,591,437 shares, while Abigail P. Johnson also …

Crexendo (CXDO) Stock Drops As Growth Strengthens But Earnings Lag

Crexendo (CXDO) stock recently dropped 11% despite strong Q2 2026 financial results, including a 48.9% revenue increase and a 17% adjusted EBITDA margin. While bulls point to significant growth in service and software solutions, bears highlight modest organic revenue growth and shifts in product …

Xeris Pharmaceuticals earnings missed by $0.19, revenue topped estimates

Why (NEWTI) Price Action Is Critical for Tactical Trading

This article analyzes the price action of Newtekone Inc. 8.00% Fixed Rate Senior Notes Due 2028 (NASDAQ: NEWTI), highlighting a neutral sentiment and a mid-channel oscillation pattern. It presents three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to …

MKTX Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of MarketAxess to Intercontinental Exchange

MONSEY, N.Y., Aug. 06, 2026 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of MarketAxess Holdings Inc. (Nasdaq: MKTX) (“MarketAxess”) to Intercontinental Exchange, Inc. (“ICE”), pursuant to which MarketAxess shareholders will receive $167.00 …

Earnings call transcript: Xeris Biopharma posts Q2 2026 revenue beat, EPS miss

Xeris Biopharma reported a Q2 2026 revenue beat of $92.1 million, surpassing Wall Street estimates, but missed EPS expectations with a loss of $0.18 per share. The company attributed the EPS miss primarily to a one-time non-cash GAAP charge related to convertible note remeasurement. …

MarketAxess Holdings (MKTX) Following ICE Bid Is Fair Value Still In Focus

MarketAxess Holdings (MKTX) is back in focus after Intercontinental Exchange's (ICE) US$6 billion acquisition bid at a 33% premium, causing a significant jump in MKTX's share price. Despite recent gains, the company's valuation narrative suggests it is still 16.9% undervalued, with a fair value …

Deluxe Corporation (NYSE: DLX) lifts profit, expands payments with Celero deal

Exelixis, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:EXEL) 2026-08-06

Exelixis, Inc. published its Q2 2026 earnings call presentation. The company reported EPS of $0.91, beating estimates by $0.02, but revenue of $628.69M missed expectations by $7.46M, despite a 10.63% year-over-year increase. The slide deck provides detailed information discussed during the earnings call.

Deluxe Corp Q2 2026: Revenue $499.3M, EPS $0.41— 10-Q Summary

Deluxe Corp reported its Q2 2026 financial results, with revenue reaching $499.3M and diluted EPS at $0.41. The company saw growth in its payments and data segments, which helped to partially offset declines in its traditional Print business. Strategic actions like cost controls, pricing …